IRLAB Therapeutics (IRLAB) Q3 2024 earnings summary

Executive summary

• Advanced clinical progress for mesdopetam (preparing for Phase III), pirepemat (Phase IIb completed enrollment), and IRL757 (Phase I ongoing), strengthening the position in Parkinson's disease treatments.

• Portfolio includes five first-in-class drug candidates targeting all stages of Parkinson's and related neurological disorders.

• New patents granted for mesdopetam (Europe) and pirepemat (US), extending exclusivity into the 2040s.

• Strategic partnerships secured, including collaboration with MSRD/Otsuka and The Michael J. Fox Foundation for IRL757, providing milestone payments and full funding for development.

• Meta-analysis presented at MDS Congress shows mesdopetam's clinically significant anti-dyskinetic effect without impaired motor function.

Financial highlights

• Cash and cash equivalents at Sep 30, 2024: SEK 90.4 million, with SEK 34 million earmarked for IRL757 and as prepayment for partner-covered costs.

• Net sales for Jan–Sep 2024: SEK 51.8 million, up from SEK 6.9 million year-over-year, mainly from research collaborations.

• Operating loss for Jan–Sep 2024: SEK -72.1 million, improved from SEK -145.1 million year-over-year.

• Cash flow from operating activities Jan–Sep 2024: SEK -43.0 million, improved from SEK -131.0 million year-over-year.

• Headcount stable at around 30–32 employees, with most in R&D.

Outlook and guidance

• Top-line data from the Phase IIb study with pirepemat expected by end of Q1 2025.

• Ongoing preparations for mesdopetam Phase III, with regulatory alignment in US and Europe; initiation pending financing.

• IRL757 Phase I studies ongoing, fully funded, with proof-of-concept study planned.

• IRL942 and IRL1117 projected to be Phase I ready in 2025.

• Active pursuit of partnerships, licensing, or capital market transactions to secure future financing.